9.20
price down icon2.75%   -0.26
after-market 시간 외 거래: 9.20
loading

Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스

pulisher
Jun 12, 2025

Bicara Therapeutics Elects New Directors at Annual Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Petri Dish: Scorpion spinout debuts with $177M, Bicara doubles footprint - The Business Journals

Jun 12, 2025
pulisher
Jun 11, 2025

# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Relay Therapeutics Strengthens Board with Precision Medicine Expert as Phase 3 Cancer Trial Approaches - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Holdings Raised by Bank of America Corp DE - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Estimates BCAX FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 10, 2025
pulisher
Jun 09, 2025

Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock - Investing.com

Jun 09, 2025
pulisher
Jun 06, 2025

Bicara Therapeutics Expands Boston Headquarters with New Lease - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

25,028 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Nuveen Asset Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Merus Raises $300m After ASCO Success - insights.citeline.com

Jun 04, 2025
pulisher
Jun 03, 2025

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Cantor Fitzgerald maintains overweight rating on Bicara stock By Investing.com - Investing.com India

Jun 03, 2025
pulisher
Jun 03, 2025

Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

Cantor Fitzgerald maintains overweight rating on Bicara stock - Investing.com

Jun 03, 2025
pulisher
Jun 02, 2025

Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

Stifel reiterates Buy rating on Bicara Therapeutics stock - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Stifel reiterates Buy rating on Bicara Therapeutics stock By Investing.com - Investing.com Canada

Jun 02, 2025
pulisher
Jun 02, 2025

Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

Bicara Responds to Rival Merus With Early Survival Data at #ASCO25 - BioSpace

Jun 02, 2025
pulisher
Jun 02, 2025

Promising Efficacy of Bicara Therapeutics’ Ficera in Combination with Pembro for HPV-Negative HNSCC Justifies Buy Rating - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Bicara presents promising early-stage data in head and neck cancers - The Business Journals

Jun 01, 2025
pulisher
Jun 01, 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - The Manila Times

Jun 01, 2025
pulisher
Jun 01, 2025

Bicara Therapeutics Reports Promising Phase 1/1b Trial Results for Ficerafusp Alfa in HPV-Negative Head and Neck Cancer - Nasdaq

Jun 01, 2025
pulisher
Jun 01, 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus ... - Enidnews.com

Jun 01, 2025
pulisher
Jun 01, 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses - GlobeNewswire

Jun 01, 2025
pulisher
Jun 01, 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - GlobeNewswire Inc.

Jun 01, 2025
pulisher
May 27, 2025

Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients - MSN

May 27, 2025
pulisher
May 27, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Shares Bought by Millennium Management LLC - Defense World

May 27, 2025
pulisher
May 26, 2025

PIZZA PIZZA ROYALTY CORP. ANNOUNCES MAY DIVIDEND and TIMING OF ANNUAL GENERAL MEETING - The Globe and Mail

May 26, 2025
pulisher
May 25, 2025

159,043 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Northern Trust Corp - Defense World

May 25, 2025
pulisher
May 25, 2025

Bicara Therapeutics (NASDAQ:BCAX) Earns “Outperform” Rating from Wedbush - Defense World

May 25, 2025
pulisher
May 25, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

May 25, 2025
pulisher
May 25, 2025

Bicara Therapeutics (NASDAQ:BCAX) Raised to Equal Weight at Wells Fargo & Company - Defense World

May 25, 2025
pulisher
May 24, 2025

Stifel maintains Bicara stock Buy rating, $48 target post-ASCO - Investing.com Australia

May 24, 2025
pulisher
May 24, 2025

Stifel maintains Bicara stock Buy rating, $48 target post-ASCO By Investing.com - Investing.com Canada

May 24, 2025
pulisher
May 24, 2025

112,476 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Deutsche Bank AG - Defense World

May 24, 2025
pulisher
May 24, 2025

Bicara falls after early-stage trial data for head and neck cancer therapy - MSN

May 24, 2025
pulisher
May 24, 2025

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics - MSN

May 24, 2025
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):